Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events
journal contributionposted on 01.10.2020, 15:08 by Olga Sobolev, Elisa Binda, Sean O'Farrell, Anna Lorenc, Joel Pradines, Yongqing Huang, Jay Duffner, Reiner Schulz, John Cason, Maria Zambon, Michael H Malim, Mark Peakman, Andrew Cope, Ishan Capila, Ganesh V Kaundinya, Adrian C Hayday
Adjuvanted vaccines afford invaluable protection against disease, and the molecular and cellular changes they induce offer direct insight into human immunobiology. Here we show that within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex molecular and cellular responses that included overt lymphoid as well as myeloid contributions. Unexpectedly, this early response was subtly but significantly different in people older than ∼35 years. Wide-ranging adverse clinical events can seriously confound vaccine adoption, but whether there are immunological correlates of these is unknown. Here we identify a molecular signature of adverse events that was commonly associated with an existing B cell phenotype. Thus immunophenotypic variation among healthy humans may be manifest in complex pathophysiological responses.
Adjuvants, ImmunologicAdolescentAdultAge FactorsAgedAntibodies, ViralAutoantibodiesAutoimmunityB-LymphocytesCluster AnalysisCytokinesFemaleGene Expression ProfilingHumansInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesInfluenza, HumanLymphocyte ActivationLymphocyte CountLymphocytesMaleMiddle AgedMyeloid CellsPhenotypeTime FactorsTranscriptomeVaccinationYoung AdultHayday FC001093Immunology1107 Immunology